MIF and metabolic dysfunction-associated steatotic liver disease: This is supported by the observation that exosomes lacking MIF are unable to facilitate the development of the pre-metastasis niche.23 More recently, a highly potent small-molecule inhibitor targeting the tautomerase activity of MIF, known as IPG1576, was developed, which substantially suppressed tumor growth in an orthotopic pancreatic cancer model.24 Given the multiple roles of MIF in both MASLD and PDAC, we hypothesize that MIF may be a key factor mediating fatty liver metastasis and a promising therapeutic target.